Skip to main content Accessibility help
×
Home
  • Cited by 2
  • Print publication year: 2011
  • Online publication date: December 2011

56 - Multiple sclerosis-associated fatigue

from Section IV - Therapy in clinical practice

Summary

More closely analogous to the use of combination therapies in multiple sclerosis (MS) is the use of combination therapies in autoimmune diseases such as rheumatoid arthritis. In the case of MS, drugs could be directed at different therapeutic domains such as tissue destruction and tissue repair. Currently, natalizumab is approved only as a monotherapy. This is due to concern over combined toxicity because of the two cases of progressive multifocal leukoencephalopathy (PML) that occurred in patients enrolled in the combination arm of the SENTINEL trial. Perhaps the most frequently used combination therapy approach utilized in clinical practice for patients with relapsing-remitting MS and continued disease activity while on platform therapy is the ad hoc addition of periodic courses of corticosteroids, most often intravenous methylprednisolone. This chapter discusses cytotoxic therapies and combination trials with other immunomodulating agents such as daclizumab, terilunomide and statins.

Related content

Powered by UNSILO

References

1. Minden, SL, Frankel D, Hadden L, Perloff J, Srinath KP, Hoaglin DC. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006; 12:24–38.
2. DeLuca J, ed. Fatigue as a Window to the Brain. Cambridge, MA: MIT Press, 2005; 336.
3. Krupp, LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988; 45:435–7.
4. Freal, JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984; 65:135–8.
5. Wessely S, Hotopf M, Sharpe D. Chronic Fatigue and its Syndromes. New York: Oxford University Press, 1988.
6. Fatigue and Multiple Sclerosis: Evidence-based management strategies for fatigue in multiple sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines, ed. M.S.C.F.C.P. Guidelines. Washington DC: Paralyzed Veterans Association of America, 1998.
7. Flachenecker P, Meissner H. Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult Scler 2008; 14:274–7.
8. Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler 2005; 11:602–9.
9. Julian, LJ, Vella L, Vollmer T, et al. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol 2008; 255:1354–60.
10. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008; 6:100.
11. Amato MP, Ponziani G, Rossi F, et al. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001; 7:340–4.
12. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997; 48:74–80.
13. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002; 205:51–8.
14. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46:1121–3.
15. Patrick E, Christodoulou C, Krupp LB. Longitudinal correlates of fatigue in multiple sclerosis. Mult Scler 2009; 15:258–61.
16. Flachenecker P, Kumpfel T, Kallmann B, et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002; 8:523–6.
17. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000; 6:181–5.
18. Edgley K, Sullivan MJ, Dehoux E. A survey of multiple sclerosis: II Determinants of employment status. Can J Rehabil 1991; 4:127–32.
19. Johansson S, Ytterberg C, Gottberg K, et al. Use of health services in people with multiple sclerosis with and without fatigue. Mult Scler 2009; 15:88–95.
20. Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients. Eur Neurol 2008; 59:136–42.
21. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61:1524–7.
22. Colosimo C, Millefiorini E, Grasso MG, et al. Fatigue in MS is associated with specific clinical features. Acta Neurol Scand 1995; 92:353–5.
23. Lerdal A, Celius EG and Moum T. Fatigue and its association with sociodemographic variables among multiple sclerosis patients. Mult Scler 2003; 9:509–14.
24. Chwastiak LA, Gibbons LE, Ehde DM, et al. Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis. J Psychosom Res 2005; 59:291–8.
25. Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008; 6:67.
26. Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry 2004; 49:157–63.
27. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996; 46:628–32.
28. Brown RF, Valpiani EM, Tennant CC, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother 2009; 82:41–56.
29. Johansson S, Ytterberg C, Hillert J, Widen Holmqvist L, von Koch L. A longitudinal study of variations in and predictors of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:454–7.
30. Bol Y, Duits AA, Hupperts RM, Vlaeyen JW, Verhey FR. The psychology of fatigue in patients with multiple sclerosis: a review. J Psychosom Res 2009; 66:3–11.
31. Schwartz CE, Coulthard-Morris L, Zeng Q. Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil 1996; 77:165–70.
32. Kroencke DC, Lynch SG, Denney DR. Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler 2000; 6:131–6.
33. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21:9–14.
34. Ford H, Trigwell P, Johnson M. The nature of fatigue in multiple sclerosis. J Psychosom Res 1998; 45:33–8.
35. Moller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 1994; 89:117–21.
36. Vercoulen JH, Swanink CM, Galama JM, et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: development of a model. J Psychosom Res 1998; 45:507–17.
37. Van Der Werf SP, Evers A, Jongen PJ, and Bleijenberg G. The role of helplessness as mediator between neurological disability, emotional instability, experienced fatigue and depression in patients with multiple sclerosis. Mult Scler 2003; 9:89–94.
38. Trojan DA, Arnold D, Collet JP, et al. Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors. Mult Scler 2007; 13:985–95.
39. Jopson NM, Moss-Morris R. The role of illness severity and illness representations in adjusting to multiple sclerosis. J Psychosom Res 2003; 54:503–11; discussion 513–14.
40. Vercoulen JH, Hommes OR, Swanink CM, et al. The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol 1996; 53:642–9.
41. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45:1956–61.
42. Feinstein A, O’Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999; 5:323–6.
43. Skerrett TN, Moss-Morris R. Fatigue and social impairment in multiple sclerosis: the role of patients’ cognitive and behavioral responses to their symptoms. J Psychosom Res 2006; 61:587–93.
44. Iriarte J, Subira ML, Castro P. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler 2000; 6:124–30.
45. Fleming WE, Pollak CP. Sleep disorders in multiple sclerosis. Semin Neurol 2005; 25:64–8.
46. Tachibana N, Howard RS, Hirsch NP, et al. Sleep problems in multiple sclerosis. Eur Neurol 1994; 34:320–3.
47. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev 2010; 14:121–9.
48. Ferini-Strambi L, Filippi M, Martinelli V, et al. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci 1994; 125:194–7.
49. Kaynak H, Altintas A, Kaynak D, et al. Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol 2006; 13:1333–9.
50. Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004; 61:525–8.
51. Moreira, NC, Damasceno RS, Medeiros CA, et al. Restless leg syndrome, sleep quality and fatigue in multiple sclerosis patients. Braz J Med Biol Res 2008; 41:932–7.
52. Veauthier C, Radbruch H, Gade G, et al. Polysomnographic investigation of frequency of sleep disorders in consecutive unselected fatigued and non-fatigued multiple sclerosis patients. Neurology 2010; 74(Suppl 2):A99.
53. Amarenco G, Kerdraon J, Denys P. [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases]. Rev Neurol (Paris) 1995;151:722–30.
54. Stanton BR, Barnes F, Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler 2006; 12:481–6.
55. Brochet B, Deloire MS, Ouallet JC, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain 2009; 25:211–17.
56. Johnson SK, Lange G, DeLuca J, Korn LR, Natelson B. The effects of fatigue on neuropsychological performance in patients with chronic fatigue syndrome, multiple sclerosis, and depression. Appl Neuropsychol 1997; 4:145–53.
57. Paul RH, Beatty WW, Schneider R, Blanco CR, Hames KA. Cognitive and physical fatigue in multiple sclerosis: relations between self-report and objective performance. Appl Neuropsychol 1998; 5:143–8.
58. Krupp LB, Elkins LE. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 2000; 55:934–9.
59. Parmenter BA, Denney DR, Lynch SG. The cognitive performance of patients with multiple sclerosis during periods of high and low fatigue. Mult Scler 2003; 9:111–18.
60. Bailey A, Channon S, Beaumont JG. The relationship between subjective fatigue and cognitive fatigue in advanced multiple sclerosis. Mult Scler 2007; 13:73–80.
61. Beatty WW, Goretti B, Siracusa G, et al. Changes in neuropsychological test performance over the workday in multiple sclerosis. Clin Neuropsychol 2003; 17:551–60.
62. Urbanek C, Weinges-Evers N, Bellmann-Strobl J, et al. Attention Network Test reveals alerting network dysfunction in multiple sclerosis. Mult Scler 2010; 16:93–9.
63. Andreasen AK, Spliid PE, Andersen H, Jakobsen J. Fatigue and processing speed are related in multiple sclerosis. Eur J Neurol 2010; 17:212–18.
64. Holtzer R, Foley F. The relationship between subjective reports of fatigue and executive control in multiple sclerosis. J Neurol Sci 2009; 281:46–50.
65. Christodoulou C. The assessment and measurement of fatigue. In Fatigue as a Window to the Brain. DeLuca J, ed. New York: MIT Press, 2005; 19–35.
66. DeLuca J. Fatigue, cognition, and mental effort. In Fatigue as a Window to the Brain. DeLuca J, ed. New York: MIT Press, 2005 37–57.
67. Hillary FG, Chiaravalloti ND, Ricker JH, et al. An investigation of working memory rehearsal in multiple sclerosis using fMRI. J Clin Exp Neuropsychol 2003; 25:965–78.
68. Staffen W, Mair A, Zauner H, et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain 2002; 125:1275–82.
69. DeLuca J, Genova HM, Hillary FG, Wylie G. Neural correlates of cognitive fatigue in multiple sclerosis using functional MRI. J Neurol Sci 2008; 270:28–39.
70. Chiaravalloti N, Hillary F, Ricker J, et al. Cerebral activation patterns during working memory performance in multiple sclerosis using FMRI. J Clin Exp Neuropsychol 2005; 27:33–54.
71. Christodoulou C, DeLuca J, Ricker JH, et al. Functional magnetic resonance imaging of working memory impairment after traumatic brain injury. J Neurol Neurosurg Psychiatry 2001; 71:161–8.
72. Kujala P, Portin R, Revonsuo A, Ruutiainen J. Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 59:77–82.
73. Schwid SR, Tyler CM, Scheid EA, et al. Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler 2003; 9:503–8.
74. Sharma KR, Kent-Braun J, Mynhier MA, Weiner MW, Miller RG. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995; 18:1403–11.
75. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120:299–315.
76. Kent-Braun JA, Sharma KR, Miller RG, Weiner MW. Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. Muscle Nerve 1994; 17:835–41.
77. Latash M, Kalugina E, Nicholas J, et al. Myogenic and central neurogenic factors in fatigue in multiple sclerosis. Mult Scler 1996; 1:236–41.
78. Schwid SR, Thornton CA, Pandya S, et al. Quantitative assessment of motor fatigue and strength in MS. Neurology 1999; 53:743–50.
79. Djaldetti R, Ziv I, Achiron A, Melamed E. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996; 46:632–5.
80. Krupp LB, Pollina DA, Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9:456–60.
81. Schubert M, Wohlfarth K, Rollnik JD, Dengler R. Walking and fatigue in multiple sclerosis: the role of the corticospinal system. Muscle Nerve 1998; 21:1068–70.
82. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18(Suppl 1):S79–83.
83. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008; 14:383–90.
84. Leocani L, Colombo B, Magnani G, et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement–EEG evidence. Neuroimage 2001; 13:1186–92.
85. Liepert J, Mingers D, Heesen C, Baumer T, Weiller C. Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study. Mult Scler 2005; 11:316–21.
86. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473–83.
87. Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976), 2000; 25:3130–9.
88. McNair DM, Lorr M, Droppleman LF. Profile of Mood States Manual. 1971, San Diego: Educational and Industrial Testing Service.
89. Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health 1975; 65:1304–10.
90. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993; 37:753–62.
91. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Mgmt 2009; 37:107–28.
92. Penner IK, Raselli C, Stocklin M, et al. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009; 15:1509–17.
93. Iriarte J, Katsamakis G, de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler 1999; 5:10–6.
94. Mills R, Young C, Nicholas R, Pallant J, Tennant A. Rasch analysis of the Fatigue Severity Scale in multiple sclerosis. Mult Scler 2009; 15:81–7.
95. Lerdal A, Johansson S, Kottorp A, von Koch L. Psychometric properties of the Fatigue Severity Scale: Rasch analyses of responses in a Norwegian and a Swedish MS cohort. Mult Scler 2010; 16:733–41.
96. Mills RJ, Young CA, Pallant JF, Tennant A. Rasch analysis of the Modified Fatigue Impact Scale (MFIS) in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1049–51.
97. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444–52.
98. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993; 37:147–53.
99. van Kessel K, Moss-Morris R, Willoughby E, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 2008; 70:205–13.
100. Mills RJ, Young CA, Pallant JF, Tennant A. Development of a patient reported outcome scale for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). Health Qual Life Outcomes 2010; 8:22.
101. Administration, US FDA, Draft guidance for industry on patient reported outcome measures: use in medicinal product development to support labeling claims. (Docket 2006D-0044). Fed Register 2006; 71:5862–5863.
102. Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45(5 Suppl 1):S22–31.
103. Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45(5 Suppl 1):S3–S11.
104. DeWalt DA, Rothrock N, Yount S, Stone AA. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; 45(5 Suppl 1):S12–21.
105. Christodoulou C, Junghaenel DU, DeWalt DA, Rothrock N, Stone AA. Cognitive interviewing in the evaluation of fatigue items: Results from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2008; 17:1239–1246.
106. Riley WT, Rothrock N, Bruce B, et al. Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banks. Qual Life Res 2010; 19:1311–21.
107. Bakshi R, Miletich RS, Henschel K, et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 1999; 53:1151–3.
108. Van Der Werf SP, Jongen PJ, Lycklama a Nijeholt GJ, et al. Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci 1998; 160:164–70.
109. Mainero C, Faroni J, Gasperini C, et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol 1999; 246:454–8.
110. Tedeschi G, Dinacci D, Lavorgna L, et al. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci 2007; 263:15–9.
111. Marrie RA, Fisher E, Miller DM, Lee JC, Rudick RA. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 2005; 228:161–6.
112. Mowry, EM, Beheshtian A, Waubant E, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72:1760–5.
113. Andreasen AK, Jakobsen J, Soerensen L et al. Regional brain atrophy in primary fatigued patients with multiple sclerosis. NeuroImage 2010; 50:608–15.
114. Sepulcre J, Masdeu JC, Goni J, et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 2009; 15:337–44.
115. Chaudhuri A, Behan PO, Fatigue in neurological disorders. Lancet 2004; 363:978–88.
116. Inglese M, Park SJ, Johnson G, et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3T. Arch Neurol 2007; 64:196–202.
117. Niepel G, Tench CR, Morgan PS, et al. Deep gray matter and fatigue in MS: a T1 relaxation time study. J Neurol 2006; 253:896–902.
118. Zellini F, Niepel G, Tench CR, Constantinescu CS. Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing–remitting multiple sclerosis. Mult Scler 2009; 15:1442–9.
119. Gallo P, Rinaldi F, Grossi P, Favaretto A, Calabrese M. Magnetic resonance evidence of the involvement of the striatal-thalamic-frontal cortex system in determining fatigue in multiple sclerosis. Neurology 2010; 74(Suppl 2):A508.
120. Tartaglia MC, Narayanan S, Francis SJ, et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004; 61:201–7.
121. Filippi M, Rocca MA. Toward a definition of structural and functional MRI substrates of fatigue in multiple sclerosis. J Neurol Sci 2007; 263:1–2.
122. Pardini M, Bonzano L, Mancardi GL, Roccatagliata L. Frontal networks play a role in fatigue perception in multiple sclerosis. Behav Neurosci 2010; 124:329–36.
123. DeLuca J, Genova HM, Capili EJ, Wylie GR. Functional neuroimaging of fatigue. Phys Med Rehabil Clin N Am 2009; 20:325–37.
124. Rocca MA, Agosta F, Colombo B, et al. fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp 2007; 28:373–82.
125. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002; 15:559–67.
126. White AT, Lee JN, Light AR, Light KC. Brain activation in multiple sclerosis: a BOLD fMRI study of the effects of fatiguing hand exercise. Mult Scler 2009; 15:580–6.
127. Tartaglia MC, Narayanan S, Arnold DL. Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue. Eur J Neurol 2008; 15:413–19.
128. Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48:1566–71.
129. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64:604–11.
130. Kerr JR, Barah F, Mattey DL, et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 2001; 82:3011–19.
131. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92(6 Suppl):1684–8.
132. Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 2001; 933:185–200.
133. Giovannoni G, Thompson AJ, Miller DH, Thompson EJ. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 2001; 57:676–81.
134. Flachenecker P, Bihler I, Weber F, et al. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 2004; 10:165–9.
135. Heesen C, Nawrath L, Reich C, et al. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006; 77:34–9.
136. Gottschalk M, Kumpfel T, Flachenecker P, et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neur 2005; 62:277–80.
137. Tellez N, Comabella M, Julia E, et al. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler 2006; 12:487–94.
138. Merkelbach S, Dillmann U, Kolmel C, Holz I, Muller M. Cardiovascular autonomic dysregulation and fatigue in multiple sclerosis. Mult Scler 2001; 7:320–6.
139. Flachenecker P, Rufer A, Bihler I, et al. Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 2003; 61:851–3.
140. Egg R, Hogl B, Glatzl S, Beer R, Berger T. Autonomic instability, as measured by pupillary unrest, is not associated with multiple sclerosis fatigue severity. Mult Scler 2002; 8:256–60.
141. Foglio K, Clini E, Facchetti D, et al. Respiratory muscle function and exercise capacity in multiple sclerosis. Eur Respir J 1994; 7:23–8.
142. Krupp LB. Fatigue in Multiple Sclerosis: A Guide to Diagnosis and Management. Demos Medical Publishing, 2004.
143. Mohr DC, Hart SL, Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom Med 2003; 65:542–7.
144. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39:432–41.
145. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62:2058–64.
146. McCullagh R, Fitzgerald AP, Murphy RP, Cooke G. Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. Clin Rehabil 2008; 22:206–14.
147. Sauter C, Zebenholzer K, Hisakawa J, Zeitlhofer J, Vass K. A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients. Mult Scler 2008; 14:500–5.
148. Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010; 75:1141–19.
149. Hugos C, Copperman L, Fuller B, et al. Clinical trial of a formal group fatigue program in multiple sclerosis. Mult Scler 2010; 16:724–32.
150. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14:273–8.
151. Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol 1988; 45:1104–6.
152. Pucci E, Branas P, D’Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007:CD002818.
153. Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 2009; 256:645–50.
154. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179–83.
155. Wingerchuk DM, Benarroch EE, O’Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64:1267–9.
156. Schwid SR, Murray TJ, Treating fatigue in patients with MS: one step forward, one step back. Neurology 2005; 64:1111–12.
157. Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2010:CD007280.
158. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002; 8:161–8.
159. Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. Mult Scler 2005; 11:459–63.
160. Geisler M, Sliwinski M, Coyle PK, et al. LB, Cooling and multiple sclerosis: cognitive and sensory effects. J Neurol Rehab 1996; 10:17–22.
161. Hugos CL, Copperman LF, Fuller BE, et al. Clinical trial of a formal group fatigue program in multiple sclerosis. Mult Scler 2010; 16:724–32.
162. Kos D, Duportail M, D’Hooghe M, Nagels G, Kerckhofs E. Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler 2007; 13:996–1003.
163. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997; 154:408–14.
164. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001; 357:841–7.
165. Sharpe M, Hawton K, Simkin S, et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial. BMJ 1996; 312:22–6.
166. Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Res 1996; 29:45–8.
167. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46:676–80.
168. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64:1139–43.
169. Littleton ET, Hobart JC, Palace J. Modafinil for multiple sclerosis fatigue: does it work? Clin Neurol Neurosurg 2010; 112:29–31.
170. Gillson G, Richard TL, Smith RB, Wright JV. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 2002; 8:30–5.
171. Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci 2009; 276:38–40.